Our Startups
Enterprise Innovation has launched a diverse portfolio of companies that are based on foundational intellectual property developed in the research laboratories of Weill Cornell Medicine. Our current portfolio of companies encompasses key health-care verticals including diagnostics, digital health, therapeutics, medical devices, and R&D products and services.
Weill Cornell Medicine Startups
VoiceLove's mission is to provide safe and easy communication for patients and health-care professionals to ultimately build patient trust and improve hospital workflow. VoiceLove is a voice messaging app that provides HIPAA compliant communication between patients, loved ones, facility staff and clergy in a medical setting. The app can be used on any smartphone and facilities can manage codes and settings from a web dashboard.
Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers. The company focuses on developing therapies for metastatic cancers by targeting key pathways related to chromosomal instability, a hallmark of cancer metastasis. The majority of oncology therapeutics target alterations widely found in primary tumors while metastasis is responsible for approximately 90% of cancer deaths. Volastra hopes to change the treatment paradigm for patients by developing novel therapeutics specifically tailored to advanced disease.
XenImmune Therapeutics, Inc.
XenImmune Therapeutics is developing a novel antibody-enzyme fusion to target tumors and trigger the robust immune response known as hyper-acute rejection.
XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. XyloCor's lead product candidate, XC001, is in clinical development for patients with refractory angina for which there are no treatment options. XyloCor also has a secondary product, XC002, in discovery stage, for patients with cardiac tissue damage from heart attacks.